For intravenous administration
Abciximab, ReoPro®, is the Fab fragment of the chimeric human-murine monoclonal
antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human
platelets and inhibits platelet aggregation. Abciximab also binds to the vitronectin (α β
receptor found on platelets and vessel wall endothelial and smooth muscle cells.
The chimeric 7E3 antibody is produced by continuous perfusion in mammalian cell
culture. The 47,615 dalton Fab fragment is purified from cell culture supernatant by a
series of steps involving specific viral inactivation and removal procedures, digestion
ReoPro® is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use.
Each single use vial contains 2 mg/mL of Abciximab in a buffered solution (pH 7.2) of
0.01 M sodium phosphate, 0.15 M sodium chloride and 0.001% polysorbate 80 in Water
for Injection. No preservatives are added.
- Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member
of the integrin family of adhesion receptors and the major platelet surface receptor
involved in platelet aggregation. Abciximab inhibits platelet aggregation by preventing
the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to
GPIIb/IIIa receptor sites on activated platelets. The mechanism of action is thought to
involve steric hindrance and/or conformational effects to block access of large molecules
to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic
Abciximab binds with similar affinity to the vitronectin receptor, also known as the α β
integrin. The vitronectin receptor mediates the procoagulant properties of platelets and
the proliferative properties of vascular endothelial and smooth muscle cells. In in vitro
studies using a model cell line derived from melanoma cells, Abciximab blocked α β
mediated effects including cell adhesion (IC50 = 0.34 µg/mL). At concentrations which,
, provide > 80% GPIIb/IIIa receptor blockade, but above the in vivo
range, Abciximab more effectively blocked the burst of thrombin generation that
followed platelet activation than select comparator antibodies which inhibit GPIIb/IIIa
alone (1). The relationship of these in vitro
data to clinical efficacy is unknown.
Abciximab also binds to the activated Mac-1 receptor on monocytes and neutrophils (2).
In in vitro
studies, Abciximab and 7E3 IgG blocked Mac-1 receptor function as
evidenced by inhibition of monocyte adhesion (3). In addition, the degree of activated
Mac-1 expression on circulating leukocytes and the numbers of circulating leukocyte-
platelet complexes has been shown to be reduced in patients treated with Abciximab
compared to control patients (4). The relationship of these in vitro
data to clinical
Maximal inhibition of platelet aggregation was observed when
≥ 80% of GPIIb/IIIa receptors were blocked by Abciximab. In non-human primates,
Abciximab bolus doses of 0.25 mg/kg generally achieved a blockade of at least 80% of
platelet receptors and fully inhibited platelet aggregation. Inhibition of platelet function
was temporary following a bolus dose, but receptor blockade could be sustained at ≥ 80%
by continuous intravenous infusion. The inhibitory effects of Abciximab were
substantially reversed by the transfusion of platelets in monkeys. The antithrombotic
efficacy of prototype antibodies [murine 7E3 Fab and F(ab′)2] and Abciximab was
evaluated in dog, monkey and baboon models of coronary, carotid, and femoral artery
thrombosis. Doses of the murine version of 7E3 or Abciximab sufficient to produce
high-grade (≥ 80%) GPIIb/IIIa receptor blockade prevented acute thrombosis and yielded
lower rates of thrombosis compared with aspirin and/or heparin.
Following intravenous bolus administration, free plasma
concentrations of Abciximab decrease rapidly with an initial half-life of less than 10
minutes and a second phase half-life of about 30 minutes, probably related to rapid
binding to the platelet GPIIb/IIIa receptors. Platelet function generally recovers over the
course of 48 hours (5,6), although Abciximab remains in the circulation for 15 days or
more in a platelet-bound state. Intravenous administration of a 0.25 mg/kg bolus dose of
Abciximab followed by continuous infusion of 10 µg/min (or a weight-adjusted infusion
of 0.125 µg/kg/min to a maximum of 10 µg/min) produces approximately constant free
plasma concentrations throughout the infusion. At the termination of the infusion period,
free plasma concentrations fall rapidly for approximately six hours then decline at a
Intravenous administration in humans of single bolus doses of
Abciximab from 0.15 mg/kg to 0.30 mg/kg produced rapid dose-dependent inhibition of
platelet function as measured by ex vivo
platelet aggregation in response to adenosine
diphosphate (ADP) or by prolongation of bleeding time. At the two highest doses (0.25
and 0.30 mg/kg) at two hours post injection (the first time point evaluated), over 80% of
the GPIIb/IIIa receptors were blocked and platelet aggregation in response to 20 µM
ADP was almost abolished. The median bleeding time increased to over 30 minutes at
both doses compared with a baseline value of approximately five minutes.
Intravenous administration in humans of a single bolus dose of 0.25 mg/kg followed by a
continuous infusion of 10 µg/min for periods of 12 to 96 hours produced sustained
high-grade GPIIb/IIIa receptor blockade (≥ 80%) and inhibition of platelet function (ex
platelet aggregation in response to 5 µM or 20 µM ADP less than 20% of baseline
and bleeding time greater than 30 minutes) for the duration of the infusion in most
patients. Similar results were obtained when a weight-adjusted infusion dose (0.125
µg/kg/min to a maximum of 10 µg/min) was used in patients weighing up to 80 kg.
Results in patients who received the 0.25 mg/kg bolus followed by a 5 µg/min infusion
for 24 hours showed a similar initial receptor blockade and inhibition of platelet
aggregation, but the response was not maintained throughout the infusion period. The
onset of Abciximab-mediated platelet inhibition following a 0.25 mg/kg bolus and 0.125
µg/kg/min infusion was rapid and platelet aggregation was reduced to less than 20% of
baseline in 8 of 10 patients at 10 minutes after treatment initiation.
Low levels of GPIIb/IIIa receptor blockade are present for more than 10 days following
cessation of the infusion. After discontinuation of Abciximab infusion, platelet function
returns gradually to normal. Bleeding time returned to ≤ 12 minutes within 12 hours
following the end of infusion in 15 of 20 patients (75%), and within 24 hours in 18 of 20
patients (90%). Ex vivo
platelet aggregation in response to 5 µM ADP returned to ≥ 50%
of baseline within 24 hours following the end of infusion in 11 of 32 patients (34%) and
within 48 hours in 23 of 32 patients (72%). In response to 20 µM ADP, ex vivo
aggregation returned to ≥ 50% of baseline within 24 hours in 20 of 32 patients (62%) and
within 48 hours in 28 of 32 patients (88%).
Abciximab has been studied in four Phase 3 clinical trials, all of which evaluated the
effect of Abciximab in patients undergoing percutaneous coronary intervention (PCI): in
patients at high risk for abrupt closure of the treated coronary vessel (EPIC), in a broader
group of patients (EPILOG), in unstable angina patients not responding to conventional
medical therapy (CAPTURE), and in patients suitable for either conventional
angioplasty/atherectomy or primary stent implantation (EPILOG Stent; EPISTENT).
Percutaneous intervention included balloon angioplasty, atherectomy, or stent placement.
All trials involved the use of various, concomitant heparin dose regimens and, unless
contraindicated, aspirin (325 mg) was administered orally two hours prior to the planned
EPIC was a multicenter, double-blind, placebo-controlled trial of Abciximab in patients
undergoing percutaneous transluminal coronary angioplasty or atherectomy (PTCA) who
were at high risk for abrupt closure of the treated coronary vessel (7). Patients were
allocated to treatment with: 1) Abciximab bolus plus infusion for 12 hours; 2) Abciximab
bolus plus placebo infusion, or; 3) placebo bolus plus infusion. All patients received
concomitant heparin (10,000 to 12,000 U bolus followed by an infusion for 12 hours).
The primary endpoint was the composite of death, myocardial infarction (MI), or urgent
intervention for recurrent ischemia within 30 days of randomization. The primary
endpoint event rates in the Abciximab bolus plus infusion group were reduced mostly in
the first 48 hours and this benefit was sustained through 30 days (7), 6 months (8), and
EPILOG was a randomized, double-blind, multicenter, placebo-controlled trial which
evaluated Abciximab in a broad population of patients undergoing PCI (excluding
patients with myocardial infarction and unstable angina meeting the EPIC high risk
criteria) (10). Study procedures emphasized discontinuation of heparin after the
procedure with early femoral arterial sheath removal and careful access site management
). EPILOG was a three-arm trial comparing Abciximab plus
standard-dose heparin, Abciximab plus low-dose heparin, and placebo plus standard-dose
heparin. Abciximab and heparin infusions were weight-adjusted in all arms. The
Abciximab bolus plus infusion regimen was: 0.25 mg/kg bolus followed by a
0.125 µg/kg/min infusion (to a maximum of 10 µg/min) for 12 hours. The heparin
regimen was either a standard-dose regimen (initial 100 U/kg bolus, target ACT ≥ 300
seconds) or a low-dose regimen (initial 70 U/kg bolus, target ACT ≥ 200 seconds).
The primary endpoint of the EPILOG trial was the composite of death or MI occurring
within 30 days of PCI. The composite of death, MI, or urgent intervention was an
important secondary endpoint. The endpoint events in the Abciximab treatment group
were reduced mostly in the first 48 hours and this benefit was sustained through 30 days
and six months (10) and one year (11). The (Kaplan-Meier) endpoint event rates at 30
ENDPOINT EVENT RATES AT 30 DAYS - EPILOG TRIAL
Acute myocardial infarctions in surviving
Urgent interventions in surviving patients
a Patients who experienced more than one event in the first 30 days are counted only once. b Patients are counted only once under the most serious component (death > acute MI >
At the six-month follow up visit, the event rate for death, MI, or repeat (urgent or
non-urgent) intervention remained lower in the Abciximab treatment arms (22.3% and
22.8%, respectively, for the standard- and low-dose heparin arms) than in the placebo
arm (25.8%) and the event rate for death, MI, or urgent intervention was substantially
lower in the Abciximab treatment arms (8.3% and 8.4%, respectively, for the standard-
and low-dose heparin arms) than in the placebo arm (14.7%). The treatment associated
effects continued to persist at the one-year follow up visit. The proportionate reductions
in endpoint event rates were similar irrespective of the type of coronary intervention used
(balloon angioplasty, atherectomy, or stent placement). Risk assessment using the
American College of Cardiology/American Heart Association clinical/morphological
criteria had large inter-observer variability. Consequently, a low risk subgroup could not
be reproducibly identified in which to evaluate efficacy.
The EPISTENT trial was a randomized, multicenter trial evaluating three different
treatment strategies in patients undergoing PCI: conventional PTCA with Abciximab plus
low-dose heparin, primary intracoronary stent implantation with Abciximab plus low-
dose heparin, and primary intracoronary stent implantation with placebo plus standard-
dose heparin (12). The heparin dose was weight-adjusted in all arms. The JJIS Palmaz-
Schatz stent was used in over 90% of the patients receiving stents. The two stent arms
were blinded with respect to study agent (Abciximab or placebo) and heparin dose; the
PCI arm with Abciximab was open-label. The Abciximab bolus plus infusion regimen
was the same as that used in the EPILOG trial. The standard-dose and low-dose heparin
regimens were the same as those used in the EPILOG trial. All patients were to receive
aspirin; ticlopidine, if given, was to be started prior to study agent. Patient and access
site management guidelines were the same as those for EPILOG, including a strong
recommendation for early sheath removal.
The results demonstrated benefit in both Abciximab arms (i.e., with and without stents)
compared with stenting alone on the composite of death, MI, or urgent intervention
(repeat PCI or CABG) within 30 days of PCI (12). The (Kaplan-Meier) endpoint event
PRIMARY ENDPOINT EVENT RATE AT 30 DAYS - EPISTENT TRIAL
Acute myocardial infarctions in surviving
Urgent interventions in surviving patients
a Patients who experienced more than one event in the first 30 days are counted only
b Patients are counted only once under the most serious component (death > acute MI >
This benefit was maintained at 6 months: 12.1% of patients in the placebo/stent group
experienced death, MI, or urgent revascularization compared with 6.4% of patients in the
Abciximab/stent group (p<0.001 vs placebo/stent) and 9.2% in the Abciximab/PTCA
group (p=0.051 vs placebo/stent). At 6 months, a reduction in the composite of death,
MI, or all repeat (urgent or non-urgent) intervention was observed in the Abciximab/stent
group compared with the placebo/stent group (15.4% vs 20.4%, p=0.006); the rate of this
composite endpoint was similar in the Abciximab/PTCA and placebo/stent groups
CAPTURE was a randomized, double-blind, multicenter, placebo-controlled trial of the
use of Abciximab in unstable angina patients not responding to conventional medical
therapy for whom PCI was planned, but not immediately performed (14). The CAPTURE
trial involved the administration of placebo or Abciximab starting 18 to 24 hours prior to
PCI and continuing until one hour after completion of the intervention.
Patients were assessed as having unstable angina not responding to conventional medical
therapy if they had at least one episode of myocardial ischemia despite bed rest and at
least two hours of therapy with intravenous heparin and oral or intravenous nitrates.
These patients were enrolled into the CAPTURE trial, if during a screening angiogram,
they were determined to have a coronary lesion amenable to PCI. Patients received a
bolus dose and intravenous infusion of placebo or Abciximab for 18 to 24 hours. At the
end of the infusion period, the intervention was performed. The Abciximab or placebo
infusion was discontinued one hour following the intervention. Patients were treated
with intravenous heparin and oral or intravenous nitrates throughout the 18- to 24-hour
Abciximab infusion period prior to the PCI.
The Abciximab dose was a 0.25 mg/kg bolus followed by a continuous infusion at a rate
of 10 µg/min. The CAPTURE trial incorporated weight adjustment of the standard
heparin dose only during the performance of the intervention, but did not investigate the
effect of a lower heparin dose, and arterial sheaths were left in place for approximately 40
hours. The primary endpoint of the CAPTURE trial was the occurrence of any of the
following events within 30 days of PCI: death, MI, or urgent intervention. The 30-day
(Kaplan-Meier) primary endpoint event rates are shown in Table 3.
PRIMARY ENDPOINT EVENT RATE AT 30 DAYS – CAPTURE TRIAL
Urgent intervention in surviving patients
a Patients who experienced more than one event in the first 30 days are counted only
once. Urgent interventions included any unplanned PCI after the planned intervention, as well as any stent placement for immediate patency and any unplanned CABG or use of an intra-aortic balloon pump.
b Patients are counted only once under the most serious component (death > acute MI >
The 30-day results are consistent with the results of the other three trials, with the greatest
effects on the myocardial infarction and urgent intervention components of the composite
endpoint. As secondary endpoints, the components of the composite endpoint were
analyzed separately for the period prior to the PCI and the period from the beginning of
the intervention through Day 30. The greatest difference in MI occurred in the
post-intervention period: the rates of MI were lower in the Abciximab group compared
with placebo (Abciximab 3.6%, placebo 6.1%). There was also a reduction in MI
occurring prior to the PCI (Abciximab 0.6%, placebo 2.0%). An Abciximab-associated
reduction in the incidence of urgent intervention occurred in the post-intervention period.
No effect on mortality was observed in either period. At six months of follow up, the
composite endpoint of death, MI, or all repeat intervention (urgent or non-urgent) was not
different between the Abciximab and placebo groups (Abciximab 31.0%, placebo 30.8%,
Mortality was uncommon in all four trials. Similar mortality rates were observed in all
arms within each trial. Patient follow-up through one year of the EPISTENT trial
suggested decreased mortality among patients treated with Abciximab and stent
placement compared to patients treated with stent alone (8/794 vs. 19/809, p=0.037).
Data from earlier studies with balloon angioplasty were not suggestive of the same
benefit. In all four trials, the rates of acute MI were significantly lower in the groups
treated with Abciximab. Most of the Abciximab treatment effect was seen in reduction in
the rate of acute non-Q-wave MI. Urgent intervention rates were also lower in
Abciximab-treated groups in these trials.
EPILOG and EPISTENT: Weight-adjusted low dose heparin, weight-adjusted
Abciximab, careful vascular access site management and discontinuation of heparin after
the procedure with early femoral arterial sheath removal were used.
The initial heparin bolus was based upon the results of the baseline ACT, according to the
ACT < 150 seconds: administer 70 U/kg heparin
ACT 150 - 199 seconds: administer 50 U/kg heparin
ACT ≥ 200 seconds: administer no heparin
Additional 20 U/kg heparin boluses were given to achieve and maintain an ACT of ≥ 200
Discontinuation of heparin immediately after the procedure and removal of the arterial
sheath within six hours were strongly recommended in the trials. If prolonged heparin
therapy or delayed sheath removal was clinically indicated, heparin was adjusted to keep
the APTT at a target of 60 to 85 seconds (EPILOG) or 55 to 75 seconds (EPISTENT).
CAPTURE trial: Anticoagulation was initiated prior to the administration of Abciximab.
Anticoagulation was initiated with an intravenous heparin infusion to achieve a target
APTT of 60 to 85 seconds. The heparin infusion was not uniformly weight adjusted in
this trial. The heparin infusion was maintained during the Abciximab infusion and was
adjusted to achieve an ACT of 300 seconds or an APTT of 70 seconds during the PCI.
Following the intervention, heparin management was as outlined above for the EPILOG
INDICATIONS AND USAGE:
Abciximab is indicated as an adjunct to percutaneous coronary intervention for the
prevention of cardiac ischemic complications
• in patients undergoing percutaneous coronary intervention
• in patients with unstable angina not responding to conventional medical therapy
when percutaneous coronary intervention is planned within 24 hours
Safety and efficacy of Abciximab use in patients not undergoing percutaneous coronary
Abciximab is intended for use with aspirin and heparin and has been studied only in that
setting, as described in CLINICAL STUDIES.
Because Abciximab may increase the risk of bleeding, Abciximab is contraindicated in
• Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of
• History of cerebrovascular accident (CVA) within two years, or CVA with a
significant residual neurological deficit
• Administration of oral anticoagulants within seven days unless prothrombin time is
• Thrombocytopenia (< 100,000 cells/µL)
• Recent (within six weeks) major surgery or trauma
• Intracranial neoplasm, arteriovenous malformation, or aneurysm
• Presumed or documented history of vasculitis
• Use of intravenous dextran before PCI, or intent to use it during an intervention
Abciximab is also contraindicated in patients with known hypersensitivity to any
component of this product or to murine proteins.
Abciximab has the potential to increase the risk of bleeding events, rarely including those
with a fatal outcome, particularly in the presence of anticoagulation, e.g., from heparin,
other anticoagulants, or thrombolytics (see ADVERSE REACTIONS: Bleeding
The risk of major bleeds due to Abciximab therapy is increased in patients receiving
thrombolytics and should be weighed against the anticipated benefits.
Should serious bleeding occur that is not controllable with pressure, the infusion of
Abciximab and any concomitant heparin should be stopped.
Allergic Reactions (including anaphylaxis)
Allergic reactions, some of which were anaphylaxis (sometimes fatal), have been
reported rarely in patients treated with ReoPro. Patients with allergic reactions should
receive appropriate treatment. Treatment of anaphylaxis should include immediate
discontinuation of ReoPro administration and initiation of resuscitative measures.
To minimize the risk of bleeding with Abciximab, it is important
to use a low-dose, weight-adjusted heparin regimen, a weight-adjusted Abciximab bolus
and infusion, strict anticoagulation guidelines, careful vascular access site management,
discontinuation of heparin after the procedure and early femoral arterial sheath removal.
Therapy with Abciximab requires careful attention to all potential bleeding sites
including catheter insertion sites, arterial and venous puncture sites, cutdown sites, needle
puncture sites, and gastrointestinal, genitourinary, pulmonary (alveolar), and
Arterial and venous punctures, intramuscular injections, and use of urinary catheters,
nasotracheal intubation, nasogastric tubes and automatic blood pressure cuffs should be
minimized. When obtaining intravenous access, non-compressible sites (e.g., subclavian
or jugular veins) should be avoided. Saline or heparin locks should be considered for
blood drawing. Vascular puncture sites should be documented and monitored. Gentle
care should be provided when removing dressings.
Femoral artery access site:
Arterial access site care is important to prevent bleeding.
Care should be taken when attempting vascular access that only the anterior wall of the
femoral artery is punctured, avoiding a Seldinger (through and through) technique for
obtaining sheath access. Femoral vein sheath placement should be avoided unless
needed. While the vascular sheath is in place, patients should be maintained on complete
bed rest with the head of the bed ≤ 30° and the affected limb restrained in a straight
position. Patients may be medicated for back/groin pain as necessary.
Discontinuation of heparin immediately upon completion of the procedure and removal
of the arterial sheath within six hours is strongly recommended if APTT ≤ 50 sec or
ACT ≤ 175 sec (see PRECAUTIONS: Laboratory Tests
). In all circumstances, heparin
should be discontinued at least two hours prior to arterial sheath removal.
Following sheath removal, pressure should be applied to the femoral artery for at least 30
minutes using either manual compression or a mechanical device for hemostasis. A
pressure dressing should be applied following hemostasis. The patient should be
maintained on bed rest for six to eight hours following sheath removal or discontinuation
of Abciximab, or four hours following discontinuation of heparin, whichever is later.
The pressure dressing should be removed prior to ambulation. The sheath insertion site
and distal pulses of affected leg(s) should be frequently checked while the femoral artery
sheath is in place and for six hours after femoral artery sheath removal. Any hematoma
should be measured and monitored for enlargement.
The following conditions have been associated with an increased risk of bleeding and
may be additive with the effect of Abciximab in the angioplasty setting: PCI within 12
hours of the onset of symptoms for acute myocardial infarction, prolonged PCI (lasting
Use of Thrombolytics, Anticoagulants and Other Antiplatelet Agents-
In the EPIC,
EPILOG, CAPTURE, and EPISTENT trials, Abciximab was used concomitantly with
heparin and aspirin. For details of the anticoagulation algorithms used in these clinical
trials, see CLINICAL STUDIES: Anticoagulation
. Because Abciximab inhibits platelet
aggregation, caution should be employed when it is used with other drugs that affect
hemostasis, including thrombolytics, oral anticoagulants, non-steroidal anti-inflammatory
In the EPIC trial, there was limited experience with the administration of Abciximab with
low molecular weight dextran. Low molecular weight dextran was usually given for the
deployment of a coronary stent, for which oral anticoagulants were also given. In the 11
patients who received low molecular weight dextran with Abciximab, five had major
bleeding events and four had minor bleeding events. None of the five placebo patients
treated with low molecular weight dextran had a major or minor bleeding event (see
Because of observed synergistic effects on bleeding, Abciximab therapy should be used
judiciously in patients who have received systemic thrombolytic therapy. The GUSTO V
trial randomized patients with acute myocardial infarction to treatment with combined
Abciximab and half-dose Reteplase, or full-dose Reteplase alone (15). In this trial, the
incidence of moderate or severe nonintracranial bleeding was increased in those patients
receiving Abciximab and half-dose Reteplase versus those receiving Reteplase alone
Thrombocytopenia, including severe thrombocytopenia, has been
observed with Abciximab administration (see ADVERSE REACTIONS:
). Platelet counts should be monitored prior to, during, and after
treatment with Abciximab. Acute decreases in platelet count should be differentiated
between true thrombocytopenia and pseudothrombocytopenia (see PRECAUTIONS:
). If true thrombocytopenia is verified, Abciximab should be
immediately discontinued and the condition appropriately monitored and treated.
In clinical trials, patients who developed thrombocytopenia were followed with daily
platelet counts until their platelet count returned to normal. Heparin and aspirin were
discontinued for platelet counts below 60,000 cells/µL and platelets were transfused for a
platelet count below 50,000 cells/µL. Most cases of severe thrombocytopenia (< 50,000
cells/µL) occurred within the first 24 hours of Abciximab administration.
In a registry study of Abciximab readministration, a history of thrombocytopenia
associated with prior use of Abciximab was predictive of an increased risk of recurrent
thrombocytopenia (see ADVERSE REACTIONS: Thrombocytopenia
within 30 days was associated with an increased incidence and severity of
thrombocytopenia, as was a positive human anti-chimeric antibody (HACA) test at
baseline, compared to the rates seen in studies with first administration.
Restoration of Platelet Function-
In the event of serious uncontrolled bleeding or the
need for emergency surgery, Abciximab should be discontinued. If platelet function does
not return to normal, it may be restored, at least in part, with platelet transfusions.
Before infusion of Abciximab, prothrombin time, ACT, APTT, and
platelet count should be measured to identify pre-existing hemostatic abnormalities.
Based on an integrated analysis of data from all studies, the following guidelines may be
utilized to minimize the risk for bleeding:
When Abciximab is initiated 18 to 24 hours before PCI, the APTT should be maintained
between 60 and 85 seconds during the Abciximab and heparin infusion period.
During PCI the ACT should be maintained between 200 and 300 seconds.
If anticoagulation is continued in these patients following PCI, the APTT should be
The APTT or ACT should be checked prior to arterial sheath removal. The sheath should
not be removed unless APTT ≤ 50 seconds or ACT ≤ 175 seconds.
Platelet counts should be monitored prior to treatment, two to four hours following the
bolus dose of Abciximab and at 24 hours or prior to discharge, whichever is first. If a
patient experiences an acute platelet decrease (e.g., a platelet decrease to less than
100,000 cells/µL and a decrease of at least 25% from pre-treatment value), additional
platelet counts should be determined. Platelet monitoring should continue until platelet
To exclude pseudothrombocytopenia, a laboratory artifact due to in vitro
interaction, blood samples should be drawn in three separate tubes containing
ethylenediaminetetraacetic acid (EDTA), citrate and heparin, respectively. A low platelet
count in EDTA but not in heparin and/or citrate is supportive of a diagnosis of
Administration of Abciximab may result in the formation of HACA
that could potentially cause allergic or hypersensitivity reactions (including anaphylaxis),
thrombocytopenia or diminished benefit upon readministration of Abciximab (see
WARNINGS: Allergic Reactions; see ADVERSE REACTIONS: Immunogenicity
Readministration of Abciximab to patients undergoing PCI was assessed in a registry that
included 1342 treatments in 1286 patients. Most patients were receiving their second
Abciximab exposure; 15% were receiving the third or subsequent exposure. The overall
rate of HACA positivity prior to the readministration was 6% and increased to 27% post-
readministration. There were no reports of serious allergic reactions or anaphylaxis (see
WARNINGS: Allergic Reactions
). Thrombocytopenia was observed at higher rates in the
readministration study than in the phase 3 studies of first-time administration (see
PRECAUTIONS: Thrombocytopenia and Adverse Reactions: Thrombocytopenia
suggesting that readministration may be associated with an increased incidence and
Formal drug interaction studies with Abciximab have not been
conducted. Abciximab has been administered to patients with ischemic heart disease
treated concomitantly with a broad range of medications used in the treatment of angina,
myocardial infarction and hypertension. These medications have included heparin,
warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin
converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.
Heparin, other anticoagulants, thrombolytics, and antiplatelet agents are associated with
an increase in bleeding. Patients with HACA titers may have allergic or hypersensitivity
reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
Carcinogenesis, Mutagenesis and Impairment of Fertility- In vitro
and in vivo
mutagenicity studies have not demonstrated any mutagenic effect. Long-term studies in
animals have not been performed to evaluate the carcinogenic potential or effects on
Pregnancy Category C-
Animal reproduction studies have not been conducted with
Abciximab. It is also not known whether Abciximab can cause fetal harm when
administered to a pregnant woman or can affect reproduction capacity. Abciximab
should be given to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk or
absorbed systemically after ingestion. Because many drugs are excreted in human milk,
caution should be exercised when Abciximab is administered to a nursing woman.
Safety and effectiveness in pediatric patients have not been studied.
Of the total number of 7860 patients in the four Phase 3 trials, 2933
(37%) were 65 and over, while 653 (8%) were 75 and over. No overall differences in
safety or efficacy were observed between patients of age 65 to less than 75 as compared
to younger patients. The clinical experience is not adequate to determine whether
patients of age 75 or greater respond differently than younger patients.
Abciximab has the potential to increase the risk of bleeding, particularly in the
presence of anticoagulation, e.g., from heparin, other anticoagulants or thrombolytics.
Bleeding in the Phase 3 trials was classified as major, minor or insignificant by the
criteria of the Thrombolysis in Myocardial Infarction study group (16). Major bleeding
events were defined as either an intracranial hemorrhage or a decrease in hemoglobin
greater than 5 g/dL. Minor bleeding events included spontaneous gross hematuria,
spontaneous hematemesis, observed blood loss with a hemoglobin decrease of more than
3 g/dL, or a decrease in hemoglobin of at least 4 g/dL without an identified bleeding site.
Insignificant bleeding events were defined as a decrease in hemoglobin of less than 3
g/dL or a decrease in hemoglobin between 3-4 g/dL without observed bleeding. In
patients who received transfusions, the number of units of blood lost was estimated
through an adaptation of the method of Landefeld, et al. (17).
In the EPIC trial, in which a non-weight-adjusted, longer-duration heparin dose regimen
was used, the most common complication during Abciximab therapy was bleeding during
the first 36 hours. The incidences of major bleeding, minor bleeding and transfusion of
blood products were significantly increased. Major bleeding occurred in 10.6% of
patients in the Abciximab bolus plus infusion arm compared with 3.3% of patients in the
placebo arm. Minor bleeding was seen in 16.8% of Abciximab bolus plus infusion
patients and 9.2% of placebo patients (7). Approximately 70% of Abciximab-treated
patients with major bleeding had bleeding at the arterial access site in the groin.
Abciximab-treated patients also had a higher incidence of major bleeding events from
gastrointestinal, genitourinary, retroperitoneal, and other sites.
Bleeding rates were reduced in the CAPTURE trial, and further reduced in the EPILOG
and EPISTENT trials by use of modified dosing regimens and specific patient
management techniques. In EPILOG and EPISTENT, using the heparin and Abciximab
dosing, sheath removal and arterial access site guidelines described under
PRECAUTIONS, the incidence of major bleeding in patients treated with Abciximab and
low-dose, weight-adjusted heparin was not significantly different from that in patients
Subgroup analyses in the EPIC and CAPTURE trials showed that non-CABG major
bleeding was more common in Abciximab patients weighing ≤ 75 kg. In the EPILOG
and EPISTENT trials, which used weight-adjusted heparin dosing, the non-CABG major
bleeding rates for Abciximab-treated patients did not differ substantially by weight
Although data are limited, Abciximab treatment was not associated with excess major
bleeding in patients who underwent CABG surgery. (The range among all treatment
arms was 3-5% in EPIC, and 1-2% in the CAPTURE, EPILOG, and EPISTENT trials.)
Some patients with prolonged bleeding times received platelet transfusions to correct the
bleeding time prior to surgery. (see PRECAUTIONS: Restoration of Platelet Function
The rates of major bleeding, minor bleeding and bleeding events requiring transfusions in
the CAPTURE, EPILOG, and EPISTENT trials are shown in Table 4. The rates of
insignificant bleeding events are not included in Table 4.
Cases of fatal bleeding have been reported rarely during post-marketing use of
Abciximab (see WARNINGS: Bleeding Events
Pulmonary alveolar hemorrhage has been rarely reported during use of Abciximab. This
can present with any or all of the following in close association with ReoPro
administration: hypoxemia, alveolar infiltrates on chest x-ray, hemoptysis, or an
NON-CABG BLEEDING IN TRIALS OF PERCUTANEOUS CORONARY
INTERVENTION (EPILOG, EPISTENT and CAPTURE)
Number of Patients with Bleeds (%)
EPILOG and EPISTENT:
a Patients who had bleeding in more than one classification are counted only once
according to the most severe classification. Patients with multiple bleeding events of the same classification are also counted once within that classification.
b Patients with major non-CABG bleeding who received packed red blood cells or
c Standard-dose heparin with or without stent (EPILOG and EPISTENT) d Low-dose heparin with or without stent (EPILOG and EPISTENT) e Standard-dose heparin (EPILOG) f Standard-dose heparin (CAPTURE)
Intracranial Hemorrhage and Stroke-
The total incidence of intracranial hemorrhage
and non-hemorrhagic stroke across all four trials was not significantly different, 9/3023
for placebo patients and 15/4680 for Abciximab-treated patients. The incidence of
intracranial hemorrhage was 3/3023 for placebo patients and 7/4680 for Abciximab
In the clinical trials, patients treated with Abciximab were more
likely than patients treated with placebo to experience decreases in platelet counts.
Among patients in the EPILOG and EPISTENT trials who were treated with Abciximab
plus low-dose heparin, the proportion of patients with any thrombocytopenia (platelets
less than 100,000 cells/µL) ranged from 2.5 to 3.0%. The incidence of severe
thrombocytopenia (platelets less than 50,000 cells/µL) ranged from 0.4 to 1.0% and
platelet transfusions were required in 0.9 to 1.1%, respectively. Modestly lower rates
were observed among patients treated with placebo plus standard-dose heparin. Overall
higher rates were observed among patients in the EPIC and CAPTURE trials treated with
Abciximab plus longer duration heparin: 2.6 to 5.2% were found to have any
thrombocytopenia, 0.9 to 1.7% had severe thrombocytopenia, and 2.1 to 5.5% required
In a readministration registry study of patients receiving a second or subsequent exposure
to Abciximab (see PRECAUTIONS: Readministration
) the incidence of any degree of
thrombocytopenia was 5%, with an incidence of profound thrombocytopenia of 2%
(<20,000 cell/µL). Factors associated with an increased risk of thrombocytopenia were a
history of thrombocytopenia on previous Abciximab exposure, readministration within 30
days, and a positive HACA assay prior to the readministration.
Among 14 patients who had thrombocytopenia associated with a prior exposure to
Abciximab, 7 (50%) had recurrent thrombocytopenia. In 130 patients with a
readministration interval of 30 days or less, 25 (19%) developed thrombocytopenia.
Severe thrombocytopenia occurred in 19 of these patients. Among the 71 patients who
had a positive HACA assay at baseline, 11 (15%) developed thrombocytopenia, 7 of
- There have been rare reports of allergic reactions, some of which
were anaphylaxis (see WARNINGS: Allergic Reactions
Other Adverse Reactions-
Table 5 shows adverse events other than bleeding and
thrombocytopenia from the combined EPIC, EPILOG and CAPTURE trials which
occurred in patients in the bolus plus infusion arm at an incidence of more than 0.5%
higher than in those treated with placebo.
ADVERSE EVENTS AMONG TREATED PATIENTS IN THE EPIC,
EPILOG, AND CAPTURE TRIALS
The following additional adverse events from the EPIC, EPILOG and CAPTURE trials
were reported by investigators for patients treated with a bolus plus infusion of
Abciximab at incidences which were less than 0.5% higher than for patients in the
Cardiovascular System: ventricular tachycardia (1.4%), pseudoaneurysm (0.8%),
palpitation (0.5%), arteriovenous fistula (0.4%), incomplete AV block (0.3%), nodal
arrhythmia (0.2%), complete AV block (0.1%), embolism (limb)(0.1%);
Gastrointestinal System: dyspepsia (2.1%), diarrhea (1.1%), ileus (0.1%),
Hemic and Lymphatic System: anemia (1.3%), leukocytosis (0.5%), petechiae (0.2%);
Nervous System: dizziness (2.9%), anxiety (1.7%), abnormal thinking (1.3%), agitation
(0.7%), hypesthesia (0.6%), confusion (0.5%) muscle contractions (0.4%), coma (0.2%),
Respiratory System: pneumonia (0.4%), rales (0.4%), pleural effusion (0.3%), bronchitis
(0.3%) bronchospasm (0.3%), pleurisy (0.2%), pulmonary embolism (0.2%), rhonchi
Urogenital System: urinary retention (0.7%), dysuria (0.4%), abnormal renal function
(0.4%), frequent micturition (0.1%), cystalgia (0.1%), urinary incontinence (0.1%),
Miscellaneous: pain (5.4%), sweating increased (1.0%), asthenia (0.7%), incisional pain
(0.6%), pruritus (0.5%), abnormal vision (0.3%), edema (0.3%), wound (0.2%), abscess
(0.2%), cellulitis (0.2%), peripheral coldness (0.2%), injection site pain (0.1%), dry
mouth (0.1%), pallor (0.1%), diabetes mellitus (0.1%), hyperkalemia (0.1%), enlarged
abdomen (0.1%), bullous eruption (0.1%), inflammation (0.1%), drug toxicity (0.1%).
As with all therapeutic proteins, there is a potential for immunogenicity. In the EPIC,
EPILOG, and CAPTURE trials, positive HACA responses occurred in approximately
5.8% of these patients receiving a first exposure to Abciximab. No increase in
hypersensitivity or allergic reactions was observed with Abciximab treatment (see
In a study of readministration of Abciximab to patients (see PRECAUTIONS:
) the overall rate of HACA positivity prior to the readministration was
6% and increased post-readministration to 27%. Among the 36 subjects receiving a
fourth or greater Abciximab exposure, HACA positive assays were observed post-
readministration in 16 subjects (44%). There were no reports of serious allergic reactions
or anaphylaxis (see WARNINGS: Allergic Reactions
). HACA positive status was
associated with an increased risk of thrombocytopenia (see PRECAUTIONS:
The data reflect the percentage of patients whose test results were considered positive for
antibodies to Abciximab using an ELISA assay, and are highly dependent on the
sensitivity and specificity of the assay. Additionally, the observed incidence of antibody
positivity in an assay may be influenced by several factors including sample handling,
timing of sample collection, concomitant medications, and underlying disease. For these
reasons, comparison of the incidence of antibodies to Abciximab with the incidence of
antibodies to other products may be misleading.
There has been no experience of overdosage in human clinical trials.
DOSAGE AND ADMINISTRATION:
The safety and efficacy of Abciximab have only been investigated with concomitant
administration of heparin and aspirin as described in CLINICAL STUDIES.
In patients with failed PCIs, the continuous infusion of Abciximab should be stopped
because there is no evidence for Abciximab efficacy in that setting.
In the event of serious bleeding that cannot be controlled by compression, Abciximab and
heparin should be discontinued immediately.
The recommended dosage of Abciximab in adults is a 0.25 mg/kg intravenous bolus
administered 10-60 minutes before the start of PCI, followed by a continuous intravenous
infusion of 0.125 µg/kg/min (to a maximum of 10 µg/min) for 12 hours.
Patients with unstable angina not responding to conventional medical therapy and who
are planned to undergo PCI within 24 hours may be treated with an Abciximab
0.25 mg/kg intravenous bolus followed by an 18- to 24-hour intravenous infusion of 10
µg/min, concluding one hour after the PCI.
Instructions for Administration
Parenteral drug products should be inspected visually for particulate matter prior
to administration. Preparations of Abciximab containing visibly opaque particles should
Hypersensitivity reactions should be anticipated whenever protein solutions such
as Abciximab are administered. Epinephrine, dopamine, theophylline, antihistamines and
corticosteroids should be available for immediate use. If symptoms of an allergic
reaction or anaphylaxis appear, the infusion should be stopped and appropriate treatment
given (see WARNINGS: Allergic Reactions
3. As with all parenteral drug products, aseptic procedures should be used during the
Withdraw the necessary amount of Abciximab for bolus injection into a syringe.
Filter the bolus injection using a sterile, non-pyrogenic, low protein-binding 0.2 or 5 µm
syringe filter (Millipore SLGV025LS or SLSV025LS or equivalent).
5. Withdraw the necessary amount of Abciximab for the continuous infusion into a
syringe. Inject into an appropriate container of sterile 0.9% saline or 5% dextrose and
infuse at the calculated rate via a continuous infusion pump. The continuous infusion
should be filtered either upon admixture using a sterile, non-pyrogenic, low
protein-binding 0.2 or 5 µm syringe filter (Millipore SLGV025LS or SLSV025LS or
equivalent) or upon administration using an in-line, sterile, non-pyrogenic, low
protein-binding 0.2 or 0.22 µm filter (Abbott #4524 or equivalent). Discard the unused
6. No incompatibilities have been shown with intravenous infusion fluids or commonly
used cardiovascular drugs. Nevertheless, Abciximab should be administered in a
separate intravenous line whenever possible and not mixed with other medications.
7. No incompatibilities have been observed with glass bottles or polyvinyl chloride bags
Abciximab (ReoPro®) 2 mg/mL is supplied in 5 mL vials containing 10 mg
Vials should be stored at 2 to 8 °C (36 to 46 °F). Do not freeze. Do not shake. Do not
use beyond the expiration date. Discard any unused portion left in the vial.
1. Reverter JC, Beguin S, Kessels H, Kumar R, Hemmer HC, Coller BS. Inhibition of
platelet-mediated, tissue-factor-induced thrombin generation by the mouse/human
chimeric 7E3 antibody; potential implications for the effect of c7E3 Fab treatment on
acute thrombosis and “clinical restenosis”. J Clin Invest
2 Alteri D, Edgington T, A monoclonal antibody reacting with distinct adhesion
molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-
1). The Journal of Immunology. 1988;141
3. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed
against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1
and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol.
4. Mickelson JK, Ali MN, Kleiman NS, Lakkis NM, Chow TW, Hughes BJ. Chimeric
7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing
coronary angioplasty. J Am Coll Cardiol. 1999;33
5. Tcheng J, Ellis SG, George BS. Pharmacodynamics of chimeric glycoprotein IIb/IIIa
integrin antiplatelet antibody Fab 7E3 in high risk coronary angioplasty. Circulation.
6. Simoons ML, de Boer MJ, van der Brand MJBM, et al. Randomized trial of a
GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation.
7. EPIC Investigators. Use of a monoclonal antibody directed against the platelet
glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med.
8. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention
with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results
at six months. Lancet.
9. Topol EJ, Ferguson JJ, Weisman HF, et al. for the EPIC Investigators. Long-term
protection from myocardial ischemic events in a randomized trial of brief integrin
blockade with percutaneous coronary intervention. JAMA.
10. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low dose
heparin during percutaneous coronary revascularization. N Eng J Med.
11. Lincoff AM, Tcheng JE, Califf RM, et al. for the EPILOG Investigators. Sustained
suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa
blockade with abciximab. Circ.
12. EPISTENT Investigators. Randomised placebo-controlled and balloon angioplasty-
controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-
IIb/IIIa blockade. Lancet.
13. Lincoff AM, Califf RM, Moliterno DJ, et al. for the EPISTENT Investigator.
Complementary clinical benefits of coronary stenting and blockade of platelet
glycoprotein IIb/IIIa receptors. N Engl J Med
14. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before,
during and after coronary intervention in refractory unstable angina: the CAPTURE
. 1997; 349
16. Rao, AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI)
Trial - Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the
fibrinolytic system in patients treated with recombinant tissue plasminogen activator and
streptokinase. J Am Coll Cardiol.
17. Landefeld, CS, Cook EF, Flatley M, et al. Identification and preliminary validation
of predictors of major bleeding in hospitalized patients starting anticoagulant therapy.
Am J Med.
0090-9556/02/3012-1311–1319DRUG METABOLISM AND DISPOSITIONU.S. Government work not protected by U.S. copyright EVALUATION OF CYTOCHROME P450 PROBE SUBSTRATES COMMONLY USED BY THE PHARMACEUTICAL INDUSTRY TO STUDY IN VITRO DRUG INTERACTIONS RAE YUAN, SORAYA MADANI, XIAO-XIONG WEI, KELLIE REYNOLDS, AND SHIEW-MEI HUANG Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Eva
1. Introducción. Los cursos de razonamiento crítico surgieron en los EE.UU. hará cosa de 30 años como reacción a las dificultades prácticas de la enseñanza de la lógica. La denominación razonamiento crítico se refiere a una actividad y no a una disciplina, a diferencia de denominaciones como lógica formal, lógica informal o teoría de la argumentación. En consonancia, el obje